Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations ...

The regulatory success of KRAS-targeting therapies marked a watershed moment, but there is room for improvement in the real world.

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role in colon cancer. Researchers also showed how this ...

The KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma cases, according to Hao Xie, MD, PhD, a medical oncologist at Mayo Clinic ...

Lumakras plus Vectibix improved overall survival and response rates in KRAS G12C-mutated metastatic colorectal cancer, despite not achieving statistical significance. The combination showed a 30% ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a Phase 3 clinical trial by ...

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and T-cell engagers.

Research shows that gastrointestinal cancers — including stomach, liver, esophageal, pancreatic, and colorectal cancers — account for about 26% of all cancers worldwide and 35% of all cancer-related ...